The Medical Letter on Drugs and Therapeutics
Insulin Glulisine (Apidra) -- A New Rapid-Acting Insulin
April 24, 2006 (Issue: 1233)Insulin glulisine (Apidra - Sanofi Aventis) is the third rapid-acting insulin analog to be marketed in the US, following insulin lispro (Humalog) and insulin aspart (Novolog). All three have a more rapid onset and shorter duration of action than...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.